JP5186145B2 - 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬又は食品組成物 - Google Patents
高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬又は食品組成物 Download PDFInfo
- Publication number
- JP5186145B2 JP5186145B2 JP2007194145A JP2007194145A JP5186145B2 JP 5186145 B2 JP5186145 B2 JP 5186145B2 JP 2007194145 A JP2007194145 A JP 2007194145A JP 2007194145 A JP2007194145 A JP 2007194145A JP 5186145 B2 JP5186145 B2 JP 5186145B2
- Authority
- JP
- Japan
- Prior art keywords
- biotin
- hyperuricemia
- blood
- uric acid
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000001431 Hyperuricemia Diseases 0.000 title claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 27
- 201000010099 disease Diseases 0.000 title description 25
- 239000000203 mixture Substances 0.000 title description 13
- 235000013305 food Nutrition 0.000 title description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 67
- 229960002685 biotin Drugs 0.000 claims description 36
- 235000020958 biotin Nutrition 0.000 claims description 36
- 239000011616 biotin Substances 0.000 claims description 36
- 210000004369 blood Anatomy 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 22
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 21
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 21
- 229940116269 uric acid Drugs 0.000 claims description 21
- 201000005569 Gout Diseases 0.000 claims description 11
- 230000001603 reducing effect Effects 0.000 claims description 7
- 206010007027 Calculus urinary Diseases 0.000 claims description 6
- 208000009911 Urinary Calculi Diseases 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 206010034568 Peripheral coldness Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000034783 hypoesthesia Diseases 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000004503 fine granule Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- -1 magnesium aluminate Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019222 white chocolate Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Progress in Medicine, Vol.14, No.12, 1994, p.50-53 東京都医師会雑誌, Vol.57, No.5, 2004, p.35-42 医薬ジャーナル,Vol. 42, No. 6, 2006, p.125-132 ビタミン広報センター, ニュースレター No.106 2003年1月号 Journal of Nutritional Biochemistry, Vol.16, No.7, 2005, p.424-427 ビタミン, Vol.78, No.3, 2004, p.175-176
(3)高尿酸血症に起因する疾患が痛風、腎障害又は尿路結石である(1)に記載の組成物、
(4)高尿酸血症に起因する疾患が心血管障害、動脈硬化性疾患又はメタボリックシンドロームである(1)に記載の組成物、
(5)高尿酸血症又はこれに起因する疾患の原因を低減させるためのビオチンを含有する組成物、
(6)肩こり、首すじのこり、手足のしびれ又は手足の冷えを予防又は治療するためのビオチンを含有する組成物及び
(7)医薬及び/又は食品として用いるための、(1)乃至(6)から選ばれるいずれか1項に記載の組成物である。
(9)ビオチンによる高尿酸血症又はこれに起因する疾患を予防又は治療する方法、
(10)ビオチンによる高尿酸血症又はこれに起因する疾患の原因を低減させる方法、
(11)ビオチンによる肩こり、首すじのこり、手足のしびれ又は手足の冷えを予防又は治療する方法及び
(12)ビオチンを含有する組成物の有効量を哺乳動物に投与する高尿酸血症又はこれに起因する疾患を予防又は治療する方法を提供する。
(1)成分
(表1)
1乃至2錠中 (mg)
−−−−−−−−−−−−−−−−−−−−−−−−−
ビオチン 1
乳糖 120
ステアリン酸マグネシウム 8
トウモロコシデンプン 50
低置換度ヒドロキシプロピルセルロース 適量
−−−−−−−−−−−−−−−−−−−−−−−−−。
(2)製法
上記成分及び分量をとり、日局製剤総則「錠剤」の項に準じて錠剤を製造する。
(1)成分
(表2)
1包中 (mg)
−−−−−−−−−−−−−−−−−−−−−−−−−
ビオチン 1
乳糖 300
ステアリン酸マグネシウム 10
D−マンニトール 900
低置換度ヒドロキシプロピルセルロース 適量
−−−−−−−−−−−−−−−−−−−−−−−−−。
(2)製法
上記成分及び分量をとり、日局製剤総則「顆粒剤」の項に準じて細粒剤を製造する。
(1)成分
(表3)
1乃至2カプセル中 (mg)
−−−−−−−−−−−−−−−−−−−−−−−−−
ビオチン 1
乳糖 90
ステアリン酸マグネシウム 6
トウモロコシデンプン 70
ヒドロキシプロピルセルロース 適量
−−−−−−−−−−−−−−−−−−−−−−−−−。
(2)製法
上記成分及び分量をとり、日局製剤総則「顆粒剤」の項に準じて細粒剤を製造した後、カプセルに充てんして硬カプセル剤を製造する。
(1)成分
(表4)
60mL中 (mg)
−−−−−−−−−−−−−−−−−−−−−−−−−
ビオチン 1
安息香酸ナトリウム 100
ポリビニルアルコール 50
白糖 900
精製水 残部
−−−−−−−−−−−−−−−−−−−−−−−−−。
(2)製法
上記成分及び分量をとり、日局製剤総則「シロップ剤」の項に準じてシロップ剤を製造した後、褐色ガラス瓶に充てんしてシロップ剤を製造する。
(1)成分
(表5)
100g中 (g)
−−−−−−−−−−−−−−−−−−−−−−−−−
ビオチン 0.001
ビターチョコレート 18
カカオバター 22
全脂粉乳 20
レシチン 0.3
バニリン 微量
砂糖 残部
−−−−−−−−−−−−−−−−−−−−−−−−−。
(2)製法
上記成分及び分量をとり、通常のチョコレート製造方法に準じて製造する。
(1)成分
(表6)
100g中 (g)
−−−−−−−−−−−−−−−−−−−−−−−−−
ビオチン 0.001
水あめ 55
クエン酸 適量
香料 微量
砂糖 残部
−−−−−−−−−−−−−−−−−−−−−−−−−。
(2)製法
上記成分及び分量をとり、通常のキャンデー製造方法に準じて製造する。
(1)成分
(表7)
100g中 (g)
−−−−−−−−−−−−−−−−−−−−−−−−−
ビオチン 0.001
小麦粉 85
食塩 適量
ショートニング 適量
イースト 3
水 残部
−−−−−−−−−−−−−−−−−−−−−−−−−。
(2)製法
上記成分及び分量をとり、通常のパン製造方法に準じて製造する。
(1)被験物質
ビオチンはDSMニュートリションジャパン(株)製のものを使用した。
(2)動物
試験動物としては、Covance Research Products Inc.からビーグル犬雄を5箇月齢で購入し、約1箇月間の検疫および馴化飼育後に使用した。
(3)投与剤形、製剤の調整方法および製剤の保存方法
試験動物毎の体重をもとに算出した必要量の被験物質を、TORPAC社のゼラチンカプセル(1/2オンス)に充填した。充填後、カプセルは動物毎に区分されたケースに入れ、投与時まで冷蔵保存した。
(4)投与経路および投与期間
被験物質を充填したカプセルは、1日1回9:00〜12:30の間に、試験動物に強制経口投与した。なお、試験動物は投与前2乃至3時間絶食させた。
(5)被験試料の調製
カプセル投与前−14および−7日(投与開始前第2週および第1週)、投与後4日、8日、12日に、橈側皮静脈から約10mL採血した。なお、採血前約18時間、試験動物は絶食させた。
(6)試験方法
血中の尿酸値は通常に用いられているUricase−POD法を用いて測定した。
(7)試験結果
ビオチン投与における各種検査値は、投与2週間前および1週間前の各種血中検査値の平均を100として換算して求めた。
被験物質 血中尿酸値の変動率%
(mg/Kg) 投与後4日 投与後8日 投与後12日
――――――――――――――――――――――――――――――――――――――
ビオチン(0.5) 103.5 86.6* 81.6**
*:p<0.05 **:p<0.01 (paired t test)
ビオチン投与により顕著な血中尿酸値の低下作用が発現した。
Claims (2)
- ビオチンを含有する、血中尿酸値を低下させるための医薬組成物。
- ビオチンを含有する、高尿酸血症、痛風、腎障害又は尿路結石を予防又は治療するための医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007194145A JP5186145B2 (ja) | 2006-08-02 | 2007-07-26 | 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬又は食品組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006211063 | 2006-08-02 | ||
JP2006211063 | 2006-08-02 | ||
JP2007194145A JP5186145B2 (ja) | 2006-08-02 | 2007-07-26 | 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬又は食品組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008056661A JP2008056661A (ja) | 2008-03-13 |
JP2008056661A5 JP2008056661A5 (ja) | 2010-07-29 |
JP5186145B2 true JP5186145B2 (ja) | 2013-04-17 |
Family
ID=39239831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007194145A Active JP5186145B2 (ja) | 2006-08-02 | 2007-07-26 | 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬又は食品組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5186145B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017038799A1 (ja) * | 2015-09-04 | 2017-03-09 | サントリーホールディングス株式会社 | ウレアーゼ活性阻害剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006089392A (ja) * | 2004-09-22 | 2006-04-06 | Tohoku Univ | 生活習慣病改善食品および生活習慣病治療薬 |
-
2007
- 2007-07-26 JP JP2007194145A patent/JP5186145B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008056661A (ja) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5207611B2 (ja) | 糖化阻害剤 | |
MX2007014587A (es) | Sistemas de distribucion. | |
JP6497764B2 (ja) | ナトリウム排出を目的とした食品組成物 | |
US20220387464A1 (en) | Inositol phosphate-containing composition | |
JPH01294631A (ja) | 糖尿性疾患治療予防剤及び飲食、し好物 | |
JP4234017B2 (ja) | リパーゼ阻害薬及びグルコマンナンを含む医薬組成物 | |
US6251421B1 (en) | Pharmaceutical composition containing psyllium fiber and a lipase inhibitor | |
TW200939975A (en) | Dietary compositions for promoting weight loss | |
TWI284529B (en) | A composition for lowering triglyceride | |
JPWO2005074961A1 (ja) | 体脂肪調整剤 | |
WO2006067925A1 (ja) | 肝機能改善剤 | |
JP6962564B2 (ja) | 筋肉損傷や筋肉疲労の抑制剤 | |
KR20060021383A (ko) | 운동 생리 기능 향상제 | |
JP5186145B2 (ja) | 高尿酸血症又はこれに起因する疾患の予防又は治療のための医薬又は食品組成物 | |
KR20130076851A (ko) | 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물 | |
KR101735061B1 (ko) | 개똥쑥 추출물, 아테미시닌 또는 디히드로아테미시닌을 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 | |
JPWO2005082390A1 (ja) | 脂肪蓄積抑制剤 | |
EP1317922B1 (fr) | Preparation antipyretique renfermant du xylitol | |
JP2008156341A (ja) | ウエスト周囲径低下剤 | |
JP2003286183A (ja) | シーナラ・スコリムスの水抽出物を有効成分とする抗アレルギー剤およびこれを含有する食品 | |
JP2007314518A (ja) | 血中ホモシステインを低下させるための組成物 | |
TWI292315B (en) | Composition for decreasing lipids in blood | |
JP7138378B2 (ja) | 結晶析出が抑制され、血糖の上昇抑制能を有するパラチノースシロップ | |
JPH10218748A (ja) | アルコール臭低減剤および飲食物 | |
JP2023000201A (ja) | 経口組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100611 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100611 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100611 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130121 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5186145 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160125 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |